The proto-oncogene cMET (mesenchymal-epithelial transition factor gene) encodes a tyrosine-kinase membrane receptor, which acts as a ligand for hepatocyte growth factor (HGF). Dysregulation of cMET and its phosphorylated form, phospho-cMET (p-cMET) have been implicated in tumor proliferation, survival, angiogenesis and migration. High expression of cMET has been shown to correlate with adverse survival outcomes in various tumor types and confers chemo-resistance and radio-resistance. The HGF/cMET axis also appears to play a key role in tumor progression in breast cancers.
Introduction
The proto-oncogene cMET (mesenchymal-epithelial transition factor gene) on chromosome 7q31 encodes a receptor tyrosine kinase (RTK) which acts as the receptor for hepatocyte growth factor (HGF) or scatter factor (SF) (1) (2) (3) . This RTK is a single-pass type I transmembrane heterodimer protein made of a disulfide bridge that links an α-chain (50 kDa) and a β-chain (145 kDa) (4) . The β-chain in cMET traverses the cell membrane and contains the cytoplasmic kinase domain and a docking site, comprised of tyrosine residues Y1349 and Y1356 (5) . HGF binding to the extracellular domain activates the intrinsic kinase activity which phosphorylates the tyrosines at the carboxyterminal docking site. Phosphorylated cMET (phospho-cMET or p-cMET) binds Grb2 (Growth factor receptor-bound protein 2) and Gab1 (GRB2-associated-binding protein 1) and activates downstream signaling molecules such as Phosphatidylinositol 3-kinase (PI3K/AKT) and Mitogen-activated protein kinase (ERK/MAPK) pathways (6, 7) . Through these cellular signaling pathways HGF/cMET interaction plays a key role in cellular proliferation, survival, migration and invasion (8) (9) (10) . The HGF/cMET axis contributes a critical physiological function in embryogenesis, angiogenesis and wound healing (11, 12) .
Multiple germline and somatic mutations in tumors result in anomalous signaling via diverse mechanisms such as activating mutations of cMET gene and over-expression of -5 -is associated with tumor progression and poor outcomes. The key role as a mitogenic, motogenic and angiogenic molecule makes HGF/cMET inhibition an attractive therapeutic strategy in cancer (23, 24) .
Overexpression of cMET has been shown to contribute to the development of invasive phenotype during progression of breast cancer in vivo and in vitro (25) . In addition, Lindemann et al. showed that differential expression of cMET between tumor and adjacent normal tissue was associated with aggressive ductal carcinoma in situ (DCIS) phenotype (26) . Prior studies have shown that protein tyrosine phosphorylation profiling of basal-like breast carcinomas is characterized by elevated tyrosine phosphorylation of cMET (27, 28) . Hence, the HGF/cMET axis seems to play a significant role in tumor progression in breast cancer (29) .
We performed an analysis of primary breast cancer specimens to evaluate the protein levels of total cMET and p-cMET by breast cancer subtype using reverse phase protein arrays (RPPA), and their correlation with patient outcome. 
Materials and Methods

Patients and tumor samples
Reverse phase protein lysate microarray (RPPA)
Protein was extracted from the human tumors and RPPA was performed in our laboratory as described previously (31) . Briefly, lysis buffer was used to lyse frozen tumors by homogenization. Tumor lysates were normalized to 1 µg/µL concentration using bicinchoninic acid assay and boiled with 1% SDS, and the supernatants were expressed as a log mean centered value after correction for protein loading using the average expression levels of over 150 proteins as previously described (31) .
Statistical Methods
Boxplots were generated for original and log2 transformed expressions of total cMET Mean and standard deviations were generated for total cMET and p-cMET by tumor subtypes. Linear regression models were used to determine if the mean total cMET and p-cMET expression was different by tumor subtypes. Martingale residual plots with lowess smooth for Cox's model for total cMET and p-cMET separately as covariate by tumor subtypes suggested a non-linear effect of total and p-cMET. A regression tree method was applied to find the best cutoff point for total cMET and p-cMET expression.
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Overall survival (OS) and corresponding censoring were computed in months from diagnosis to death for each patient. Relapse-free survival (RFS) was regarded as the time to first relapse after diagnosis. Median RFS and OS were estimated nonparametrically with the use of Kaplan-Meier curves by patient characteristics and levels of total cMET and p-cMET expression and compared by the log-rank statistic.
Log-rank tests were used to evaluate the hazard ratio by total cMET and p-cMET expression levels among all patients and patients within each subtype. Cox proportional hazards models were fit to determine the association of cMET and p-cMET levels with the risk of recurrence and death after adjustment for other patient and disease characteristics. Table 3 summarizes the median RFS estimates by c-MET and p-cMET expression and by tumor subtypes. Dichotomized total cMET expression (cutoff point 0) was a significant prognostic factor for RFS (HR: 2.44, 95% CI: 1.34-4.44, P = 0.003). Estimated 5-year RFS rates were 61.3% (95% CI: 53.2%-70.7%) and 78.9% (95% CI: 68.6%-90.8%) for patients with high cMET and low cMET level, respectively (P = 0.003). Likewise, dichotomized p-cMET expression (cutoff point 0.35) was also a significant prognostic factor for RFS (HR: 1.64, 95% CI: 1.04-2.60, P = 0.033) and estimated 5-year RFS rates for patients with high p-cMET and low p-cMET levels were 58.9% (95% CI: 49.1%-70.7%) and 73.8% (95% CI: 65.6%-83.1%), respectively (P = 0.033). Total cMET was also a significant predictor of RFS within the HR-positive subtype (HR: 3.44, 95% CI:
Results
Median
1.21-9.81, P = 0.014). In contrast, p-cMET was a significant predictor of RFS within the HER2-positive subtype (HR: 3.02, 95% CI: 1.15-7.96, P = 0.019). The Kaplan-Meier survival curves for RFS for all patients and by breast tumor subtypes are as shown in figure 1. Although, there was a trend towards worse RFS with high cMET levels (HR 2.36; 95% CI: 0.86-6.51) in triple-negative subtype, this did not reach statistical significance (P = 0.086). Table 3 summarizes the median OS estimates by c-MET and p-cMET expression and by tumor subtypes. At the time of analysis, 207 of the 257 patients (80.5%) were still alive.
As was seen with RFS analysis, dichotomized cMET level was a significant prognostic factor of OS (HR: 3.18, 95% CI: 1.43-7.11, P = 0.003). Estimated 5-year OS rates were 72.4% (95% CI: 64.7%-81.0%) and 93.3% (95% CI: 87.8%-99.2%) for patients with high cMET and low cMET levels, respectively (P = 0.003). Dichotomized p-cMET level was a significant prognostic factor of OS (HR: 1.92, 95% CI: 1.08-3.44, P = 0.025). The To evaluate whether cMET confers radioresistance, we performed an exploratory subgroup analysis among 164 patients who received radiation therapy. Dichotomized total cMET level was a significant prognostic factor for both RFS (HR 3.37; 95% CI: 1.50-7.57, P = 0.002) and OS (HR 4.03; 95% CI: 1.39-11.67, P = 0.006) for patients who received radiation therapy. Similarly, dichotomized p-cMET was a significant prognostic factor for RFS (HR 2.07; 95% CI: 1.12-3.84, P = 0.017) and OS (HR 2.25; 95% CI: 1.05-4.85, P = 0.033) in this group. In contrast, among 93 patients who did not receive radiation therapy, total cMET and p-cMET were not significant prognostic factors for either RFS or OS.
Research. 
Discussion
The cMET proto-oncogene encodes a RTK which binds with high affinity to its ligand HGF/SF (1). This receptor-ligand interaction leads to formation of phosphorylated cMET which activates downstream effectors such as PI3K (Phosphatidylinositol 3 kinase)-AKT, PLC γ (Phospholipase C γ), RAS-MAPK (mitogen-activated protein kinase), c-Src and STATs (signal transducer and activator of transcription) (4, 5) . Together this cascade contributes to carcinogenesis and angiogenesis in a wide variety of human malignancies including cervical, endometrial, gastric, kidney, liver, sarcoma, lung, colorectal and breast (4) .
In this analysis of 257 breast cancer samples we demonstrated that increased levels of total cMET and p-cMET using RPPA are seen in nearly 70% and 50% of breast cancers, respectively. We also show that there is no significant difference in the levels of total cMET and p-cMET among different breast cancer subtypes. Survival analysis reveals that total cMET and p-cMET levels are significant prognostic factors for both RFS and OS. Analysis of survival outcomes among various tumor subtypes show that high cMET levels is a poor prognostic factor for hormone receptor-positive breast cancer and high p-cMET levels is a poor prognostic factor for HER2-positive breast cancers.
A number of studies have shown correlation of cMET expression with progression, aggressive behavior and poor survival outcomes in breast cancers (33) (34) (35) (36) . However, no study, to the best of our knowledge, has yet investigated the significance of differential expression of cMET and p-cMET in the different breast cancer subtypes (HR-positive, HER2-positive and TNBC. Also, there are no studies reporting p-cMET levels as a prognostic factor in breast cancer. Previous work studying this receptor has been performed using enzyme-linked immunosorbent assay (ELISA), immunoperoxidase HGF/cMET signaling enhances the transition from pre-invasive DCIS to invasive carcinoma (39) . The pathway also promotes cell motility and angiogenesis (11, 40) .
HGF-dependent β-catenin stabilization leads to the establishment of bone metastasis in breast cancers (41) . HGF/cMET receptor signals synergize with HER2 and promote breakdown of cell-cell junctions and enhance cell invasiveness (42) . This cross talk is possibly responsible for poor prognosis seen in HER2-positive breast cancers with high levels of p-cMET (RFS: P = 0.019 and OS: P = 0.014).
Development of therapy resistance is a major cause of treatment failure in breast cancer. In vitro studies have shown that HGF/SF/cMET signaling pathway can confer resistance against induction of apoptosis by various DNA damaging-agents (radiation and cytotoxic agents such as anthracyclines and taxanes) (43) . Moreover, the pathway is also involved in promoting cell survival by enhancing DNA repair (44) . Studies also 
